Enterprise Value
202.1M
Cash
103.4M
Avg Qtr Burn
-14.58M
Short % of Float
55.44%
Insider Ownership
60.69%
Institutional Own.
12.49%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SEL-212 (Pegadricase) Details Chronic refractory gout, Arthritis | BLA Submission | |
Descartes-08 Details Myasthenia gravis | Phase 2b Update | |
Descartes-08 Details Systemic lupus erythematosus | Phase 2 Data readout | |
SEL-302 (MMA-101 + ImmTOR) Details Genetic disorder, Methylmalonic acidemia | Phase 1/2 Interim update |